| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
A randomized trial of therapies for type 2 diabetes and coronary artery disease.
|
N Engl J Med
|
2009
|
12.15
|
|
2
|
Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes.
|
N Engl J Med
|
2015
|
5.81
|
|
3
|
Rationale, design, and methods for glycemic control in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial.
|
Am J Cardiol
|
2006
|
3.17
|
|
4
|
Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
|
Am Heart J
|
2008
|
2.40
|
|
5
|
Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial.
|
Am J Cardiol
|
2006
|
2.25
|
|
6
|
Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
|
Circulation
|
2013
|
2.15
|
|
7
|
Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
|
Circulation
|
2011
|
1.81
|
|
8
|
Effects of optimal medical treatment with or without coronary revascularization on angina and subsequent revascularizations in patients with type 2 diabetes mellitus and stable ischemic heart disease.
|
Circulation
|
2011
|
1.75
|
|
9
|
The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction.
|
Circulation
|
2009
|
1.57
|
|
10
|
Health status after treatment for coronary artery disease and type 2 diabetes mellitus in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial.
|
Circulation
|
2010
|
1.56
|
|
11
|
Prognostic impact of the presence and absence of angina on mortality and cardiovascular outcomes in patients with type 2 diabetes and stable coronary artery disease: results from the BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) trial.
|
J Am Coll Cardiol
|
2013
|
1.55
|
|
12
|
Coronary artery bypass in patients with type 2 diabetes: experience from the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial.
|
J Thorac Cardiovasc Surg
|
2014
|
1.47
|
|
13
|
Relation of severe coronary artery narrowing to insulin or thiazolidinedione use in patients with type 2 diabetes mellitus (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes Study).
|
Am J Cardiol
|
2009
|
1.42
|
|
14
|
Modifications of coronary risk factors.
|
Am J Cardiol
|
2006
|
1.41
|
|
15
|
Risk factor control for coronary artery disease secondary prevention in large randomized trials.
|
J Am Coll Cardiol
|
2013
|
1.40
|
|
16
|
SYNTAX Score and Long-Term Outcomes: The BARI-2D Trial.
|
J Am Coll Cardiol
|
2017
|
1.40
|
|
17
|
Factors related to the selection of surgical versus percutaneous revascularization in diabetic patients with multivessel coronary artery disease in the BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes) trial.
|
JACC Cardiovasc Interv
|
2009
|
1.38
|
|
18
|
Rationale for the revascularization arm of the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial.
|
Am J Cardiol
|
2006
|
1.37
|
|
19
|
The effect of obesity on quality of life in patients with diabetes and coronary artery disease.
|
Am Heart J
|
2010
|
1.21
|
|
20
|
Future directions for cardiovascular disease comparative effectiveness research: report of a workshop sponsored by the National Heart, Lung, and Blood Institute.
|
J Am Coll Cardiol
|
2012
|
1.09
|
|
21
|
Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort.
|
J Peripher Nerv Syst
|
2009
|
1.09
|
|
22
|
Clinical and angiographic risk stratification and differential impact on treatment outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
|
Circulation
|
2012
|
1.04
|
|
23
|
Baseline coronary angiographic findings in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial (BARI 2D).
|
Am J Cardiol
|
2009
|
0.97
|
|
24
|
Burgeoning dilemmas in the management of diabetes and cardiovascular disease: rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial.
|
Circulation
|
2003
|
0.95
|
|
25
|
Impact of completeness of revascularization on long-term cardiovascular outcomes in patients with type 2 diabetes mellitus: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D).
|
Circ Cardiovasc Interv
|
2012
|
0.92
|
|
26
|
Association between albuminuria and duration of diabetes and myocardial dysfunction and peripheral arterial disease among patients with stable coronary artery disease in the BARI 2D study.
|
Mayo Clin Proc
|
2010
|
0.92
|
|
27
|
Comparison of plasminogen activator inhibitor-1, tissue type plasminogen activator antigen, fibrinogen, and D-dimer levels in various age decades in patients with type 2 diabetes mellitus and stable coronary artery disease (from the BARI 2D trial).
|
Am J Cardiol
|
2009
|
0.91
|
|
28
|
Comprehensive Cardiovascular Risk Factor Control Improves Survival: The BARI 2D Trial.
|
J Am Coll Cardiol
|
2015
|
0.90
|
|
29
|
Racial differences in the association between self-rated health status and objective clinical measures among participants in the BARI 2D trial.
|
Am J Public Health
|
2010
|
0.90
|
|
30
|
Peroxisome proliferator-activated receptor pathway gene polymorphism associated with extent of coronary artery disease in patients with type 2 diabetes in the bypass angioplasty revascularization investigation 2 diabetes trial.
|
Circulation
|
2011
|
0.89
|
|
31
|
Gated SPECT perfusion imaging for the simultaneous assessment of myocardial perfusion and ventricular function in the BARI 2D trial: an initial report from the Nuclear Core Laboratory.
|
J Nucl Cardiol
|
2006
|
0.89
|
|
32
|
Risk factors for incident peripheral arterial disease in type 2 diabetes: results from the Bypass Angioplasty Revascularization Investigation in type 2 Diabetes (BARI 2D) Trial.
|
Diabetes Care
|
2014
|
0.88
|
|
33
|
Sex differences in presentation and outcome among patients with type 2 diabetes and coronary artery disease treated with contemporary medical therapy with or without prompt revascularization: a report from the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation 2 Diabetes).
|
J Am Coll Cardiol
|
2013
|
0.86
|
|
34
|
High prevalence and diversity of kidney dysfunction in patients with type 2 diabetes mellitus and coronary artery disease: the BARI 2D baseline data.
|
Am J Med Sci
|
2010
|
0.85
|
|
35
|
Resting heart rate and metabolic syndrome in patients with diabetes and coronary artery disease in bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) trial.
|
Prev Cardiol
|
2010
|
0.84
|
|
36
|
Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort.
|
Diabetes Care
|
2013
|
0.82
|
|
37
|
Relationships of obesity and fat distribution with atherothrombotic risk factors: baseline results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
|
Obesity (Silver Spring)
|
2009
|
0.82
|
|
38
|
The impact of race/ethnicity on baseline characteristics and the burden of coronary atherosclerosis in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial.
|
Am Heart J
|
2011
|
0.81
|
|
39
|
Ancillary studies in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial: Synergies and opportunities.
|
Am J Cardiol
|
2006
|
0.80
|
|
40
|
Association between increased platelet P-selectin expression and obesity in patients with type 2 diabetes: a BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) substudy.
|
Diabetes Care
|
2009
|
0.80
|
|
41
|
Change in albuminuria and eGFR following insulin sensitization therapy versus insulin provision therapy in the BARI 2D study.
|
Clin J Am Soc Nephrol
|
2013
|
0.80
|
|
42
|
Economic outcomes of treatment strategies for type 2 diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial.
|
Circulation
|
2009
|
0.79
|
|
43
|
Economic evaluation of alternative strategies to treat patients with diabetes mellitus and coronary artery disease.
|
Am J Cardiol
|
2006
|
0.79
|
|
44
|
Prognostic Value of Adipokines in Predicting Cardiovascular Outcome: Explaining the Obesity Paradox.
|
Mayo Clin Proc
|
2016
|
0.78
|
|
45
|
Race/ethnic disparities in risk factor control and survival in the bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) trial.
|
Am J Cardiol
|
2013
|
0.78
|
|
46
|
Appropriate revascularization in stable angina: lessons from the BARI 2D trial.
|
Can J Cardiol
|
2014
|
0.78
|
|
47
|
Body mass index and health status in the Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial (BARI 2D).
|
Am Heart J
|
2011
|
0.78
|
|
48
|
Control of lipids at baseline in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
|
Prev Cardiol
|
2009
|
0.78
|
|
49
|
Favorable effects of insulin sensitizers pertinent to peripheral arterial disease in type 2 diabetes: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
|
Diabetes Care
|
2013
|
0.77
|
|
50
|
Aggregator: a machine learning approach to identifying MEDLINE articles that derive from the same underlying clinical trial.
|
Methods
|
2014
|
0.77
|
|
51
|
Sex, Prescribing Practices and Guideline Recommended, Blood Pressure, and LDL Cholesterol Targets at Baseline in the BARI 2D Trial.
|
Int J Endocrinol
|
2015
|
0.77
|
|
52
|
The effect of age on clinical outcomes and health status BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes).
|
J Am Coll Cardiol
|
2011
|
0.75
|
|
53
|
Influence of Total Coronary Occlusion on Clinical Outcomes (from the Bypass Angioplasty Revascularization Investigation 2 DiabetesTrial).
|
Am J Cardiol
|
2016
|
0.75
|
|
54
|
Statement of the problem.
|
Am J Cardiol
|
2006
|
0.75
|
|
55
|
Health insurance status and control of diabetes and coronary artery disease risk factors on enrollment into the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
|
Diabetes Educ
|
2010
|
0.75
|